Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2000 | 03-2000 | 12-1999 | 09-1999 | 06-1999 | |
| Assets | |||||
| Current Assets | |||||
| Other current assets | 0 | 0 | 2,320 | 3,610 | 3,440 |
| TOTAL | $N/A | $N/A | $2,320 | $3,610 | $3,440 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 6,060 | 1,230 | 1,280 | 440 | 500 |
| TOTAL | $6,060 | $1,230 | $1,280 | $440 | $500 |
| Total Assets | $6,060 | $1,230 | $3,600 | $4,050 | $3,940 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 760 | 1,130 | 590 | 760 | 1,070 |
| Accrued Expenses | 2,000 | 2,080 | 3,720 | 2,260 | 1,820 |
| Other current liabilities | 810 | 1,510 | 3,370 | 3,100 | 2,050 |
| TOTAL | $5,700 | $6,850 | $9,810 | $8,250 | $7,020 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 2,830 | 0 | 0 |
| TOTAL | $2,140 | $2,520 | $2,830 | $3,340 | $3,830 |
| Total Liabilities | $7,840 | $9,370 | $12,640 | $11,590 | $10,850 |
| Shareholders' Equity | |||||
| Common Shares | 20 | 20 | 10 | 10 | 10 |
| Other shareholders' equity | -1,990 | -2,210 | -2,840 | -3,780 | -2,510 |
| TOTAL | $188,450 | $187,930 | $110,740 | $109,630 | $109,100 |
| Total Liabilities And Equity | $196,290 | $197,300 | $123,380 | $121,220 | $119,950 |